Cancer Innovation Journey
Jonathan shares his journey through the biotech landscape, highlighting the significant strides made in cancer treatment over the past five years. He emphasizes the promise of immunotherapy, particularly checkpoint inhibitors, which have shown potential for long-term remission and even cures in a subset of patients. The discussion also touches on the importance of early-stage investment in groundbreaking companies like Arasca, aiming to eradicate Ras-driven cancers.In this clip
From this podcast
Raising Health
From Surgeon to Biotech CEO with Jonathan Lim
Related Questions